Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer
At the present time, a small group of patients with oligometastases (who have a solitary metastatic lesion in another organ along with the primary tumour of the lung) is differentiated among the patients with metastatic lung cancer. A total of 14 patients of the study citied in this article underwen...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2759 |
| _version_ | 1827962389151088640 |
|---|---|
| author | D. I. Yudin K. K. Laktionov D. T. Marinov V. V. Breder A. K. Allakhverdiev T. N. Borisova A. H. Bekyashev K. P. Laktionov V. A. Aleshin M. S. Ardzinba |
| author_facet | D. I. Yudin K. K. Laktionov D. T. Marinov V. V. Breder A. K. Allakhverdiev T. N. Borisova A. H. Bekyashev K. P. Laktionov V. A. Aleshin M. S. Ardzinba |
| author_sort | D. I. Yudin |
| collection | DOAJ |
| description | At the present time, a small group of patients with oligometastases (who have a solitary metastatic lesion in another organ along with the primary tumour of the lung) is differentiated among the patients with metastatic lung cancer. A total of 14 patients of the study citied in this article underwent a comprehensive treatment of oligometastatic non-small cell lung cancer (ONSCLC), which included systemic therapy and local influence on solitary metastasis. The median overall survival for this group was 20 months (16.0–32.6, CI 95%). The 1-year and 2-year overall survival rates accounted for 84.5 and 65.7%, respectively. The findings of the study demonstrate the possibilities of an aggressive approach to the treatment of patients with ONLDLC. |
| first_indexed | 2024-04-09T16:41:50Z |
| format | Article |
| id | doaj.art-f5af76aa98d74b2f871fc63c111f1a4b |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:41:50Z |
| publishDate | 2018-11-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-f5af76aa98d74b2f871fc63c111f1a4b2023-04-23T06:56:40ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-11-0101912212510.21518/2079-701X-2018-19-122-1252701Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancerD. I. Yudin0K. K. Laktionov1D. T. Marinov2V. V. Breder3A. K. Allakhverdiev4T. N. Borisova5A. H. Bekyashev6K. P. Laktionov7V. A. Aleshin8M. S. Ardzinba9Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowAt the present time, a small group of patients with oligometastases (who have a solitary metastatic lesion in another organ along with the primary tumour of the lung) is differentiated among the patients with metastatic lung cancer. A total of 14 patients of the study citied in this article underwent a comprehensive treatment of oligometastatic non-small cell lung cancer (ONSCLC), which included systemic therapy and local influence on solitary metastasis. The median overall survival for this group was 20 months (16.0–32.6, CI 95%). The 1-year and 2-year overall survival rates accounted for 84.5 and 65.7%, respectively. The findings of the study demonstrate the possibilities of an aggressive approach to the treatment of patients with ONLDLC.https://www.med-sovet.pro/jour/article/view/2759nsclcoligometastatic diseaselung cancer |
| spellingShingle | D. I. Yudin K. K. Laktionov D. T. Marinov V. V. Breder A. K. Allakhverdiev T. N. Borisova A. H. Bekyashev K. P. Laktionov V. A. Aleshin M. S. Ardzinba Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer Медицинский совет nsclc oligometastatic disease lung cancer |
| title | Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer |
| title_full | Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer |
| title_fullStr | Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer |
| title_full_unstemmed | Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer |
| title_short | Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer |
| title_sort | intermediate results of combination therapy in patients with oligometastatic non small cell lung cancer |
| topic | nsclc oligometastatic disease lung cancer |
| url | https://www.med-sovet.pro/jour/article/view/2759 |
| work_keys_str_mv | AT diyudin intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT kklaktionov intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT dtmarinov intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT vvbreder intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT akallakhverdiev intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT tnborisova intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT ahbekyashev intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT kplaktionov intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT vaaleshin intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer AT msardzinba intermediateresultsofcombinationtherapyinpatientswitholigometastaticnonsmallcelllungcancer |